Close

We use cookies to improve your experience of our website. Privacy Policy

Skip to main content
Menu

Dr Gianmichele Massimo

Gianmichele Massimo

Postdoctoral Researcher

Centre for Cardiovascular Medicine and Devices (WHRI)
Queen Mary University of London
0207 8825720

ResearcherID LinkedIn

Research

My research activity aims to understand how genetic mutations of xanthine oxidoreductase enzyme (XOR), the rate-limiting enzyme of purines (hypoxanthine, xanthine) metabolism, affect its activity in terms of uric acid, reactive oxygen species and nitric oxide production.

Cardiovascular Models

Interests

My research activity aims to understand whether genetic mutations of xanthine oxidoreductase enzyme (XOR), altering its structure, expression and activity, have a role in the development of endothelial dysfunction and ultimately in cardiovascular disease. There are numerous evidence supporting the concept that raised levels of circulating UA represent an independent risk factor for cardiovascular diseases (like heart failure), as well as numerous evidence showing that under pathophysiological conditions, such as ischemia-reperfusion, hypertension, atherosclerosis, diabetes, XOR activity and expression are upregulated. There is also some evidence suggesting that non-synonymous genetic mutations of XDH alter its expression and activity. To investigate how this mutations modulate the expression, the tertiary structure and its activity, I have developed a 2D in vitro model of WT and mutated hXOR HEK-293 cells.

Publications

Publications of specific relevance to Predictive in vitro Models

2021

Gee LC, Massimo G, Lau C, Primus C, Fernandes D, Chen J, Rathod KS, Hamers AJP, Filomena F, Nuredini G, Ibrahim AS, Khambata RS, Gupta AK, Moon JC, Kapil V and Ahluwalia A (2021). Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide. British Journal of Pharmacology  10.1111/bph.15636

2020

Kapil V, Khambata RS, Jones DA, Rathod K, Primus C, Massimo G, Fukuto JM and Ahluwalia A (2020). The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. Pharmacological Reviews  vol. 72, (3) 692-766. 10.1124/pr.120.019240

2018

Chen J, Hamers AJP, Finsterbusch M, Massimo G, Zafar M, Corder R, Colas RA, Dalli J, Thiemermann C and Ahluwalia A (2018). Endogenously generated arachidonate-derived ligands for TRPV1 induce cardiac protection in sepsis. Faseb J  fj201701303-fj201701303. 10.1096/fj.201701303R